{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:07:00Z","timestamp":1792516020297,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T00:00:00Z","timestamp":1528243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1038\/s41416-018-0133-7","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T16:04:19Z","timestamp":1528128259000},"page":"424-428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study"],"prefix":"10.1038","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4580-585X","authenticated-orcid":false,"given":"Simon","family":"Pernot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Le Malicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Lep\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Lecaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysiane","family":"Marthey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Palle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Zaanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"key":"133_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69\u201390 (2011).","journal-title":"CA Cancer J. Clin."},{"key":"133_CR2","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1245\/s10434-013-3466-8","volume":"21","author":"ZM Bamboat","year":"2014","unstructured":"Bamboat, Z. M. et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann. Surg. Oncol. 21, 1678\u20131685 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"133_CR3","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1200\/JCO.2012.42.6635","volume":"30","author":"S Taghavi","year":"2012","unstructured":"Taghavi, S., Jayarajan, S., Davey, A. & Willis, A. Prognostic significance of signet ring gastric cancer. J. Clin. Oncol. 30, 3493\u20133498 (2012).","journal-title":"J. Clin. Oncol."},{"key":"133_CR4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.5858\/2004-128-765-DTITIA","volume":"128","author":"DE Henson","year":"2004","unstructured":"Henson, D. E., Dittus, C., Younes, M., Nguyen, H. & Albores-Saavedra, J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch. Pathol. Lab Med. 128, 765\u2013770 (2004).","journal-title":"Arch. Pathol. Lab Med."},{"key":"133_CR5","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner, A. D. et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24, 2903\u20132909 (2006).","journal-title":"J. Clin. Oncol."},{"issue":"suppl 5","key":"133_CR6","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","volume":"27","author":"EC Smyth","year":"2016","unstructured":"Smyth, E. C. et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. J. Eur. Soc. Med. Oncol. 27(suppl 5), v38\u2013v49 (2016).","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"133_CR7","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Cutsem Van","year":"2006","unstructured":"Van Cutsem, E. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 24, 4991\u20134997 (2006).","journal-title":"J. Clin. Oncol."},{"key":"133_CR8","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.2006.10.4968","volume":"25","author":"JA Ajani","year":"2007","unstructured":"Ajani, J. A. et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J. Clin. Oncol. 25, 3205\u20133209 (2007).","journal-title":"J. Clin. Oncol."},{"key":"133_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham, D. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36\u201346 (2008).","journal-title":"N. Engl. J. Med."},{"key":"133_CR10","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran, S.-E. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol. 26, 1435\u20131442 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"133_CR11","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.2017.35.15_suppl.4004","volume":"35","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran, S.-E. et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil\/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF\/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J. Clin. Oncol. 35(15_suppl), 4004\u20134004 (2017).","journal-title":"J. Clin. Oncol."},{"key":"133_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10120-013-0266-6","volume":"17","author":"S Pernot","year":"2014","unstructured":"Pernot, S. et al. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. Gastric Cancer 17, 341\u2013347 (2014).","journal-title":"Gastric Cancer"},{"key":"133_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/SLA.0b013e3182352647","volume":"254","author":"M Messager","year":"2011","unstructured":"Messager, M. et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann. Surg. 254, 684\u2013693 (2011). discussion 693.","journal-title":"Ann. Surg."},{"key":"133_CR14","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1245\/s10434-013-3462-z","volume":"21","author":"U Heger","year":"2014","unstructured":"Heger, U. et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?. Ann. Surg. Oncol. 21, 1739\u20131748 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"133_CR15","first-page":"1263","volume":"30A","author":"P Rougier","year":"1994","unstructured":"Rougier, P. et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur. J. Cancer Oxf. Engl. 1990 30A, 1263\u20131269 (1994).","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"133_CR16","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.21873\/anticanres.11138","volume":"36","author":"N Lemoine","year":"2016","unstructured":"Lemoine, N. et al. Signet ring cells and efficacy of first-line chemotherapy in advanced gastric or oesogastric junction adenocarcinoma. Anticancer Res. 36, 5543\u20135549 (2016).","journal-title":"Anticancer Res."},{"key":"133_CR17","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.3748\/wjg.v21.i40.11428","volume":"21","author":"S Pernot","year":"2015","unstructured":"Pernot, S. et al. Signet-ring cell carcinoma of the stomach: impact on prognosis and specific therapeutic challenge. World J. Gastroenterol. 21, 11428\u201311438 (2015).","journal-title":"World J. Gastroenterol."},{"key":"133_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet Lond. Engl. 383, 31\u201339 (2014).","journal-title":"Lancet Lond. Engl."},{"key":"133_CR19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224\u20131235 (2014).","journal-title":"Lancet Oncol."},{"key":"133_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y.-J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet Lond. Engl. 376, 687\u2013697 (2010).","journal-title":"Lancet Lond. Engl."},{"key":"133_CR21","unstructured":"Bang Y.-J., et al. Relationship between PDL1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J. Clin. Oncol. [cit\u00e9 28 juin 2015]; Disponible sur: http:\/\/meetinglibrary.asco.org\/content\/150958-156"},{"key":"133_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12032-014-0159-5","volume":"31","author":"L Chen","year":"2014","unstructured":"Chen, L. et al. Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients. Med. Oncol. North. Lond. Engl. 31, 159 (2014).","journal-title":"Med. Oncol. North. Lond. Engl."},{"key":"133_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13045-015-0148-y","volume":"8","author":"S Kim","year":"2015","unstructured":"Kim, S. et al. The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas. J. Hematol. Oncol. 8, 52 (2015).","journal-title":"J. Hematol. Oncol."},{"key":"133_CR24","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran, S.-E. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 17, 1697\u20131708 (2016).","journal-title":"Lancet Oncol."},{"key":"133_CR25","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","volume":"17","author":"O Glehen","year":"2010","unstructured":"Glehen, O. et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann. Surg. Oncol. 17, 2370\u20132377 (2010).","journal-title":"Ann. Surg. Oncol."},{"key":"133_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/archsurg.139.1.20","volume":"139","author":"O Glehen","year":"2004","unstructured":"Glehen, O. et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch. Surg. Chic. 139, 20\u201326 (2004).","journal-title":"Arch. Surg. Chic."},{"key":"133_CR27","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1002\/cncr.25356","volume":"116","author":"O Glehen","year":"2010","unstructured":"Glehen, O. et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116, 5608\u20135618 (2010).","journal-title":"Cancer"},{"key":"133_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0039-6060(96)80145-0","volume":"119","author":"Y Yonemura","year":"1996","unstructured":"Yonemura, Y. et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 119, 437\u2013444 (1996).","journal-title":"Surgery"},{"key":"133_CR29","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran, S.-E. et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 Trial. JAMA Oncol. 3, 1237\u20131244 (2017).","journal-title":"JAMA Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0133-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0133-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0133-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:33Z","timestamp":1684616553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0133-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0133-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,6]]},"assertion":[{"value":"4 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no funding sources.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The original studies were conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki, and the study protocol was approved by institutional review boards or ethics committees of all participating sites.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Data are available in FFCD data centre.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}